Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Neoplasms 2Melanoma 2Lung Neoplasms 1Locally Advanced Rectal Adenocarcinoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 150Radiotherapy 121Cetuximab 96Docetaxel 60Fluorouracil 56Paclitaxel 45Radiotherapy, Intensity-Modulated 41Carboplatin 40pembrolizumab 34Surveys and Questionnaires 22Erlotinib Hydrochloride 19Nivolumab 18Immunohistochemistry 16Gefitinib 16Drug Therapy 16Gemcitabine 14Pemetrexed 13Gene Expression Profiling 13durvalumab 12Chemotherapy, Adjuvant 12Radiation 11Filgrastim 11Bevacizumab 11Surgical Procedures, Operative 10Polymerase Chain Reaction 10Amifostine 10Celecoxib 9Capecitabine 9Standard of Care 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Head and Neck Neoplasms × sotigalimab × Clear all
NCT02482168 2023-12-20

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Apexigen America, Inc.

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryHead & Neck

Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡